Skip to main content

Advertisement

Advertisement

ADVERTISEMENT

Research in Review

Highlights from the 63rd American Society of Hematology (ASH) Annual Meeting

February 2022

J Clin Pathways. 2022;8;(1):10-15.

Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL

Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.

First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting

In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.

Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States

Study results presented at the 2021 ASH Annual Meeting provide valuable real-world data on current treatment patterns and decision-making for patients with MM.

Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting

Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.

Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM

In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.

Advertisement

Advertisement

Advertisement